Holdings Channel
Play Video: The Importance of Insider Buying


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree CRL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Other companies seeing insider buying close in time to when the Charles River Laboratories International Insider Buying occurred are:

The RealReal Insider Buying
Ocuphire Pharma Insider Buying
Dollar General Insider Buying
Pacific Premier Bancorp Insider Buying
Design Therapeutics Insider Buying
Edesa Biotech Insider Buying
Hallador Energy Insider Buying
Lenz Therapeutics Inc New Insider Buying
Comstock Resources Insider Buying
Purple Innovation Insider Buying

Charles River Laboratories International insider buying image
The table below summarizes the most recent Charles River Laboratories International insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Charles River Laboratories International insider buys are important for investors to follow.
DateInsiderPriceAmount
8-24-2023
Insider Buy
Richard F. Wallman
Director
$198.79
CAGR »
$198,786.00
1,000 shares
2-23-2023
Insider Buy
Richard F. Wallman
Director
$220.73
CAGR »
$386,277.50
1,750 shares
12-2-2022
Insider Buy
Richard F. Wallman
Director
$218.90
CAGR »
$328,350.00
1,500 shares
11-2-2020
Insider Buy
Richard F. Wallman
Director
$233.20
CAGR »
$1,679,006.47
7,200 shares

Also See: Institutional Holders of CRL
Also See: SEC filings

CRL Performance Since Insider Purchase
Below we present the annualized performance delivered by Charles River Laboratories International stock since 8-24-2023 (the date of the most recent insider purchase). The performance of the investment from the time Charles River Laboratories International insider buying occurred is the ultimate test of whether insiders were right about CRL being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/25/2023
End date: 04/23/2024
Start price/share: $200.39
End price/share: $240.13
Dividends collected/share: $0.00
Total return: 19.83%
Annualized Gain: 29.91%
Starting investment: $10,000.00
Ending investment: $11,983.00
Years: 0.66

Charles River Laboratories International Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Charles River Laboratories International insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding CRL

Charles River Laboratories International Insider Buying | www.HoldingsChannel.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.